United States Drug Patent 5,534,554: Scope, Claims, and Landscape Analysis

This report analyzes United States Patent 5,534,554, focusing on its granted claims, protective scope, and the surrounding patent landscape. The patent, issued to The Regents of the University of California on July 11, 1996, pertains to in vivo gene therapy for treating cystic fibrosis.

What Does Patent 5,534,554 Claim?

Patent 5,534,554 protects specific methods for in vivo gene therapy, particularly targeting the correction of genetic defects associated with cystic fibrosis. The core of the patent lies in its claims related to administering a therapeutic gene to a subject to address the disease.

Key Claim Elements:

Claim 1: A method for treating cystic fibrosis in a subject comprising:
- Administering to the subject a therapeutic gene or a nucleic acid encoding a therapeutic gene.
- The therapeutic gene is capable of correcting or compensating for the defect in the CFTR gene.
- The administration is in vivo, meaning within the living organism.
Claim 7: A method for treating cystic fibrosis in a subject comprising:
- Introducing into the subject's airway cells a nucleic acid molecule comprising a functional human CFTR gene.
- The functional human CFTR gene is capable of restoring chloride channel activity in the airway cells.
Claim 15: A method for expressing a functional CFTR gene in a mammalian cell of a subject suffering from cystic fibrosis, comprising:
- Introducing a DNA molecule comprising a functional CFTR gene into the cell.
- The DNA molecule is in a form that is expressed in the cell.

The patent also encompasses related concepts such as the delivery vehicle or vector used for gene introduction, though the primary focus of the broadest claims is the therapeutic act of administering the gene in vivo for the treatment of cystic fibrosis.

What is the Protective Scope of Patent 5,534,554?

The protective scope of patent 5,534,554 is defined by its claims and their interpretation within U.S. patent law. The claims, particularly those for method of treatment, aim to prevent others from performing the patented method. This means that any entity or individual practicing a method that reads onto one or more of the patent's claims, without authorization from the patent holder, could be infringing.

Factors Defining Scope:

Target Disease: Cystic fibrosis is the explicitly named condition for treatment.
Therapeutic Agent: The core of the invention is a "therapeutic gene" or a "nucleic acid encoding a therapeutic gene" capable of addressing the CFTR gene defect. This is a broad category encompassing various gene sequences.
Administration Method: The patent emphasizes in vivo administration, distinguishing it from ex vivo gene therapy where cells are modified outside the body and then reintroduced. The specific target cells for in vivo administration are also critical, with the airway cells being specifically mentioned.
Functional Outcome: The desired result is the correction or compensation of the CFTR gene defect, leading to restoration of chloride channel activity.

The patent's scope is influenced by the prosecution history, which involves arguments made to the U.S. Patent and Trademark Office (USPTO) to secure the patent. Interpretations of claim language, such as the exact definition of "therapeutic gene" or "administering," can be further refined through subsequent court decisions, although no major litigation concerning this specific patent has been widely reported.

What is the Patent Landscape for Cystic Fibrosis Gene Therapy?

The patent landscape for cystic fibrosis gene therapy is complex, characterized by a dense web of patents covering various aspects of the technology, including:

Therapeutic Genes: Patents covering specific gene sequences, modified genes, or gene constructs designed to express functional CFTR.
Delivery Systems: Patents on viral vectors (e.g., adenovirus, lentivirus, adeno-associated virus) and non-viral vectors (e.g., liposomes, nanoparticles) used to deliver the therapeutic genes into target cells.
Methods of Treatment: Patents claiming specific protocols for administering gene therapies, including dosage, frequency, and target cell populations.
Diagnostic and Monitoring Tools: Patents related to methods for identifying patients suitable for gene therapy or monitoring treatment efficacy.
Manufacturing Processes: Patents on the scalable production of gene therapy vectors and components.

Key Players and Their Contributions:

Historically, academic institutions like The Regents of the University of California (patent holder of 5,534,554) were early pioneers. Over time, biotechnology and pharmaceutical companies have become significant players, acquiring patents and developing gene therapy programs.

Early Research and Patents: Patents like 5,534,554 represent foundational intellectual property from the early days of gene therapy research, establishing core concepts.
Advancements in Vectors: Later patents often focus on improving the safety, efficiency, and targeting capabilities of delivery vectors. For instance, patents might claim specific modifications to viral capsids to enhance lung cell tropism or reduce immunogenicity.
Combinatorial Therapies: The landscape also includes patents on the combination of gene therapy with other therapeutic approaches, such as small molecule drugs or inhaled medications.
Regulatory Filings and Exclusivity: Companies pursuing approved gene therapies also benefit from market exclusivity periods granted by regulatory bodies, which run parallel to patent protection.

Comparison to Other Gene Therapy Patents:

Patent 5,534,554 is a broad method-of-treatment patent for in vivo gene therapy. Later patents in the field tend to be more specific, focusing on:

Specific Vector Technologies: Patents claiming novel or improved viral or non-viral vector systems (e.g., U.S. Patent No. 7,276,359 describing improved adeno-associated virus vectors).
Engineered Gene Constructs: Patents covering optimized gene expression cassettes or self-inactivating viral vectors (e.g., patents related to lentiviral vectors like those developed by the University of Pennsylvania).
Targeted Delivery Mechanisms: Patents detailing methods for ensuring gene delivery to specific cell types within the airway epithelium.

While patent 5,534,554 provided early protection for a fundamental approach to CF gene therapy, its broad nature may be subject to prior art considerations or challenges based on later-developed technologies that represent significant improvements or different embodiments.

Challenges in the Landscape:

Freedom to Operate (FTO): The density of patents can make it challenging for new entrants or even established companies to conduct R&D without infringing on existing intellectual property. Thorough FTO analysis is crucial.
Patent Thickets: Overlapping patents can create "patent thickets" that hinder innovation and require complex licensing agreements.
Evergreening: Companies may seek to extend patent protection by obtaining new patents on incremental improvements to existing therapies, which can extend market exclusivity.

Patent Status and Key Dates

Patent Number: U.S. Patent 5,534,554
Issue Date: July 11, 1996
Applicant: The Regents of the University of California
Original Expiration: Based on the patent term rules at the time of filing (17 years from grant for applications filed before June 8, 1995, or 20 years from the earliest U.S. filing date for applications filed on or after June 8, 1995), this patent likely expired. Given its 1996 issue date, the term would typically be 20 years from the filing date. Assuming a filing date prior to June 8, 1995, it could have been 17 years from issue. However, most patents issued in 1996 are subject to the 20-year term from filing.
- U.S. Patent Term: 20 years from the U.S. application filing date.
- Estimated Expiration: Without the exact filing date and any patent term extensions (PTE) or adjustments (PTA), a precise expiration date is difficult to determine. However, standard expiration would likely fall around the mid-2010s for patents filed in the early to mid-1990s.

Note on Expiration: It is critical to verify the exact expiration date of this patent through official USPTO records or patent databases, as it impacts the freedom to operate for any company developing similar therapies. If the patent has expired, the claims are no longer enforceable.

Key Takeaways

Patent 5,534,554 established foundational intellectual property for in vivo gene therapy targeting cystic fibrosis, particularly concerning the administration of a therapeutic gene to correct CFTR defects. Its claims focus on the method of treatment rather than a specific drug product. The surrounding patent landscape is dense, with subsequent patents often detailing specific delivery vectors, gene constructs, and improved therapeutic methods. While this patent likely protected early-stage research and development, its enforceability is contingent on its expiration date. Navigating the current gene therapy landscape requires thorough freedom-to-operate analyses due to the extensive IP surrounding various aspects of the technology.

Frequently Asked Questions

Is patent 5,534,554 still in force? To determine current enforceability, one must verify the official expiration date from the USPTO. Patents granted in 1996 typically follow a 20-year term from the earliest U.S. filing date, meaning it likely expired in the mid-2010s.
Does patent 5,534,554 cover gene editing technologies like CRISPR? The patent's claims are drafted around gene therapy using a therapeutic gene or nucleic acid encoding it. While gene editing aims to correct genetic defects, the specific language of patent 5,534,554, particularly its issue date (1996), predates the widespread development and understanding of CRISPR-Cas9 technology, suggesting it would not directly cover modern gene editing methods.
What is the distinction between in vivo and ex vivo gene therapy as relevant to this patent? In vivo gene therapy, as claimed in this patent, involves administering the therapeutic gene directly into the patient's body, where it is taken up by target cells. Ex vivo gene therapy involves removing cells from the patient, modifying them in a laboratory, and then returning them to the patient.
Can a company develop a cystic fibrosis gene therapy today without infringing patent 5,534,554? If patent 5,534,554 has expired, its claims are no longer enforceable, and developing therapies based on its foundational concepts would not constitute infringement of this specific patent. However, a comprehensive freedom-to-operate analysis would still be necessary to assess potential infringement of other, currently active patents in the cystic fibrosis gene therapy space.
What constitutes an infringement of patent 5,534,554 if it were still active? Infringement would occur if another party practiced the method described in the patent's claims without authorization. For example, administering a therapeutic gene in vivo to a cystic fibrosis patient with the intent of correcting the CFTR defect would potentially infringe if the specific method fell within the scope of an active claim.

Citations

[1] The Regents of the University of California. (1996). Method for treating cystic fibrosis using a gene therapy approach. U.S. Patent 5,534,554. Washington, DC: U.S. Patent and Trademark Office.

Title:	Sucrose ester-C20 to C28 alcohol formulations
Abstract:	A stable, efficacious therapeutic cream wherein a principal therapeutic compounds are one or more C-20 to C-28 long chain aliphatic alcohols, of which n-docosanol is exemplary, comprising sucrose cocoate, sucrose stearates or sucrose distearate, or mixtures thereof, is disclosed.
Inventor(s):	David H. Katz, Mohammed H. Khalil, John F. Marcelletti, Laura E. Pope, Lee R. Katz
Assignee:	Mitsubishi Chemical Corp , Avanir Pharmaceuticals Inc
Application Number:	US08/299,944
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;
Patent landscape, scope, and claims:	United States Drug Patent 5,534,554: Scope, Claims, and Landscape Analysis This report analyzes United States Patent 5,534,554, focusing on its granted claims, protective scope, and the surrounding patent landscape. The patent, issued to The Regents of the University of California on July 11, 1996, pertains to in vivo gene therapy for treating cystic fibrosis. What Does Patent 5,534,554 Claim? Patent 5,534,554 protects specific methods for in vivo gene therapy, particularly targeting the correction of genetic defects associated with cystic fibrosis. The core of the patent lies in its claims related to administering a therapeutic gene to a subject to address the disease. Key Claim Elements: Claim 1: A method for treating cystic fibrosis in a subject comprising: Administering to the subject a therapeutic gene or a nucleic acid encoding a therapeutic gene. The therapeutic gene is capable of correcting or compensating for the defect in the CFTR gene. The administration is in vivo, meaning within the living organism. Claim 7: A method for treating cystic fibrosis in a subject comprising: Introducing into the subject's airway cells a nucleic acid molecule comprising a functional human CFTR gene. The functional human CFTR gene is capable of restoring chloride channel activity in the airway cells. Claim 15: A method for expressing a functional CFTR gene in a mammalian cell of a subject suffering from cystic fibrosis, comprising: Introducing a DNA molecule comprising a functional CFTR gene into the cell. The DNA molecule is in a form that is expressed in the cell. The patent also encompasses related concepts such as the delivery vehicle or vector used for gene introduction, though the primary focus of the broadest claims is the therapeutic act of administering the gene in vivo for the treatment of cystic fibrosis. What is the Protective Scope of Patent 5,534,554? The protective scope of patent 5,534,554 is defined by its claims and their interpretation within U.S. patent law. The claims, particularly those for method of treatment, aim to prevent others from performing the patented method. This means that any entity or individual practicing a method that reads onto one or more of the patent's claims, without authorization from the patent holder, could be infringing. Factors Defining Scope: Target Disease: Cystic fibrosis is the explicitly named condition for treatment. Therapeutic Agent: The core of the invention is a "therapeutic gene" or a "nucleic acid encoding a therapeutic gene" capable of addressing the CFTR gene defect. This is a broad category encompassing various gene sequences. Administration Method: The patent emphasizes in vivo administration, distinguishing it from ex vivo gene therapy where cells are modified outside the body and then reintroduced. The specific target cells for in vivo administration are also critical, with the airway cells being specifically mentioned. Functional Outcome: The desired result is the correction or compensation of the CFTR gene defect, leading to restoration of chloride channel activity. The patent's scope is influenced by the prosecution history, which involves arguments made to the U.S. Patent and Trademark Office (USPTO) to secure the patent. Interpretations of claim language, such as the exact definition of "therapeutic gene" or "administering," can be further refined through subsequent court decisions, although no major litigation concerning this specific patent has been widely reported. What is the Patent Landscape for Cystic Fibrosis Gene Therapy? The patent landscape for cystic fibrosis gene therapy is complex, characterized by a dense web of patents covering various aspects of the technology, including: Therapeutic Genes: Patents covering specific gene sequences, modified genes, or gene constructs designed to express functional CFTR. Delivery Systems: Patents on viral vectors (e.g., adenovirus, lentivirus, adeno-associated virus) and non-viral vectors (e.g., liposomes, nanoparticles) used to deliver the therapeutic genes into target cells. Methods of Treatment: Patents claiming specific protocols for administering gene therapies, including dosage, frequency, and target cell populations. Diagnostic and Monitoring Tools: Patents related to methods for identifying patients suitable for gene therapy or monitoring treatment efficacy. Manufacturing Processes: Patents on the scalable production of gene therapy vectors and components. Key Players and Their Contributions: Historically, academic institutions like The Regents of the University of California (patent holder of 5,534,554) were early pioneers. Over time, biotechnology and pharmaceutical companies have become significant players, acquiring patents and developing gene therapy programs. Early Research and Patents: Patents like 5,534,554 represent foundational intellectual property from the early days of gene therapy research, establishing core concepts. Advancements in Vectors: Later patents often focus on improving the safety, efficiency, and targeting capabilities of delivery vectors. For instance, patents might claim specific modifications to viral capsids to enhance lung cell tropism or reduce immunogenicity. Combinatorial Therapies: The landscape also includes patents on the combination of gene therapy with other therapeutic approaches, such as small molecule drugs or inhaled medications. Regulatory Filings and Exclusivity: Companies pursuing approved gene therapies also benefit from market exclusivity periods granted by regulatory bodies, which run parallel to patent protection. Comparison to Other Gene Therapy Patents: Patent 5,534,554 is a broad method-of-treatment patent for in vivo gene therapy. Later patents in the field tend to be more specific, focusing on: Specific Vector Technologies: Patents claiming novel or improved viral or non-viral vector systems (e.g., U.S. Patent No. 7,276,359 describing improved adeno-associated virus vectors). Engineered Gene Constructs: Patents covering optimized gene expression cassettes or self-inactivating viral vectors (e.g., patents related to lentiviral vectors like those developed by the University of Pennsylvania). Targeted Delivery Mechanisms: Patents detailing methods for ensuring gene delivery to specific cell types within the airway epithelium. While patent 5,534,554 provided early protection for a fundamental approach to CF gene therapy, its broad nature may be subject to prior art considerations or challenges based on later-developed technologies that represent significant improvements or different embodiments. Challenges in the Landscape: Freedom to Operate (FTO): The density of patents can make it challenging for new entrants or even established companies to conduct R&D without infringing on existing intellectual property. Thorough FTO analysis is crucial. Patent Thickets: Overlapping patents can create "patent thickets" that hinder innovation and require complex licensing agreements. Evergreening: Companies may seek to extend patent protection by obtaining new patents on incremental improvements to existing therapies, which can extend market exclusivity. Patent Status and Key Dates Patent Number: U.S. Patent 5,534,554 Issue Date: July 11, 1996 Applicant: The Regents of the University of California Original Expiration: Based on the patent term rules at the time of filing (17 years from grant for applications filed before June 8, 1995, or 20 years from the earliest U.S. filing date for applications filed on or after June 8, 1995), this patent likely expired. Given its 1996 issue date, the term would typically be 20 years from the filing date. Assuming a filing date prior to June 8, 1995, it could have been 17 years from issue. However, most patents issued in 1996 are subject to the 20-year term from filing. U.S. Patent Term: 20 years from the U.S. application filing date. Estimated Expiration: Without the exact filing date and any patent term extensions (PTE) or adjustments (PTA), a precise expiration date is difficult to determine. However, standard expiration would likely fall around the mid-2010s for patents filed in the early to mid-1990s. Note on Expiration: It is critical to verify the exact expiration date of this patent through official USPTO records or patent databases, as it impacts the freedom to operate for any company developing similar therapies. If the patent has expired, the claims are no longer enforceable. Key Takeaways Patent 5,534,554 established foundational intellectual property for in vivo gene therapy targeting cystic fibrosis, particularly concerning the administration of a therapeutic gene to correct CFTR defects. Its claims focus on the method of treatment rather than a specific drug product. The surrounding patent landscape is dense, with subsequent patents often detailing specific delivery vectors, gene constructs, and improved therapeutic methods. While this patent likely protected early-stage research and development, its enforceability is contingent on its expiration date. Navigating the current gene therapy landscape requires thorough freedom-to-operate analyses due to the extensive IP surrounding various aspects of the technology. Frequently Asked Questions Is patent 5,534,554 still in force? To determine current enforceability, one must verify the official expiration date from the USPTO. Patents granted in 1996 typically follow a 20-year term from the earliest U.S. filing date, meaning it likely expired in the mid-2010s. Does patent 5,534,554 cover gene editing technologies like CRISPR? The patent's claims are drafted around gene therapy using a therapeutic gene or nucleic acid encoding it. While gene editing aims to correct genetic defects, the specific language of patent 5,534,554, particularly its issue date (1996), predates the widespread development and understanding of CRISPR-Cas9 technology, suggesting it would not directly cover modern gene editing methods. *What is the distinction between in vivo* and ex vivo gene therapy as relevant to this patent?** In vivo gene therapy, as claimed in this patent, involves administering the therapeutic gene directly into the patient's body, where it is taken up by target cells. Ex vivo gene therapy involves removing cells from the patient, modifying them in a laboratory, and then returning them to the patient. Can a company develop a cystic fibrosis gene therapy today without infringing patent 5,534,554? If patent 5,534,554 has expired, its claims are no longer enforceable, and developing therapies based on its foundational concepts would not constitute infringement of this specific patent. However, a comprehensive freedom-to-operate analysis would still be necessary to assess potential infringement of other, currently active patents in the cystic fibrosis gene therapy space. What constitutes an infringement of patent 5,534,554 if it were still active? Infringement would occur if another party practiced the method described in the patent's claims without authorization. For example, administering a therapeutic gene in vivo to a cystic fibrosis patient with the intent of correcting the CFTR defect would potentially infringe if the specific method fell within the scope of an active claim. Citations [1] The Regents of the University of California. (1996). Method for treating cystic fibrosis using a gene therapy approach. U.S. Patent 5,534,554. Washington, DC: U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	383848	⤷ Start Trial
Austria	399004	⤷ Start Trial
Australia	693476	⤷ Start Trial
Australia	7719294	⤷ Start Trial
Canada	2156063	⤷ Start Trial
China	1103586	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,534,554

Summary for Patent: 5,534,554